Cost-effectiveness analysis of first and second-generation EGFR tyrosine kinase inhibitors as first line of treatment for patients with NSCLC harboring EGFR mutations

Cost-effectiveness analysis of first and second-generation EGFR tyrosine kinase inhibitors as first line of treatment for patients with NSCLC harboring EGFR mutations

Abstract Background Tyrosine-kinase inhibitors (TKIs) have become the cornerstone treatment of patients with non-small cell lung cancer that harbor oncogenic EGFR mutations. The counterpart of these drugs is the financial burden that they impose, which often creates a barrier for accessing treatment...

Full description

Bibliographic Details
Main Authors: Oscar Arrieta, Rodrigo Catalán, Silvia Guzmán-Vazquez, Feliciano Barrón, Luis Lara-Mejía, Herman Soto-Molina, Maritza Ramos-Ramírez, Diana Flores-Estrada, Jaime de la Garza
Format: Article
Language:English
Published: BMC 2020-09-01
Series:BMC Cancer
Subjects:
Lung adenocarcinoma
Treatment cost
Cost-effectiveness
Economic burden
Online Access:http://link.springer.com/article/10.1186/s12885-020-07329-8

Internet

http://link.springer.com/article/10.1186/s12885-020-07329-8

Similar Items